COMBINATION COMPRISING VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE

(19)

(11)

EP 1 507 529 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	24.02.2010 Bulletin 2010/08

(45)	Mention of the grant of the patent:
	22.04.2009 Bulletin 2009/17

(21)	Application number: 03732397.9

(22)	Date of filing: 16.05.2003

(51)

International Patent Classification (IPC):

A61K 31/4184^(2006.01)
C07D 401/12^(2006.01)
A61K 31/196^(2006.01)

A61K 31/19^(2006.01)
A61K 31/44^(2006.01)

(86)	International application number:
	PCT/EP2003/005180

(87)	International publication number:
	WO 2003/097045 (27.11.2003 Gazette 2003/48)

(54)	COMBINATION COMPRISING VALSARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE KOMBINATION ENTHALTEND VALSARTAN, AMLODIPIN UND HYDROCHLOROTHIAZID COMBINAISON COMPRENANT VALSARTANE, AMLODIPINE ET HYDROCHLOROTHIAZIDE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30)

Priority:

17.05.2002 US 381547 P

(43)	Date of publication of application:
	23.02.2005 Bulletin 2005/08

(73)	Proprietors:
	Novartis AG 4056 Basel (CH) Designated Contracting States: TR BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK Novartis Pharma GmbH 1230 Wien (AT) Designated Contracting States: AT

(72)	Inventors:
	SHETTY, Suraj, Shivappa Far Hills, NJ 07931 (US) WEBB, Randy, Lee Flemington, NJ 08822 (US)

(74)	Representative: de Weerd, Petrus G.W. et al
	Novartis International AG Corporate Intellectual Property 4002 Basel 4002 Basel (CH)

(56)

References cited: :

WO-A-92/20342
DE-A- 19 820 151

DE-A- 10 004 651
US-A- 5 656 650

MACGREGOR G A ET AL: "THE EFFICACY OF CANDESARTAN: AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST ALONE OR IN COMBINATION WITH AMLODIPINE OR IN COMBINATION WITH AMLODIPINE AND HYDROCHLOROTHIAZIDE IN PATIENTS WITH MODERATE-TO-SEVERE ESSENTIAL HYPERTENSION" AMERICAN JOURNAL OF HYPERTENSION, NEW YORK, NY, US, vol. 10, no. 4, PART 2, April 1997 (1997-04), page 112A XP000869500
MACGREGOR G A ET AL: "Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension" HYPERTENSION 2000 UNITED STATES, vol. 36, no. 3, 2000, pages 454-460, XP002251650 ISSN: 0194-911X
OPARIL SUZANNE ET AL: "Efficacy and safety of Losartan/Hydrochlorothiazide in patients with severe hypertension." AMERICAN JOURNAL OF CARDIOLOGY, vol. 87, no. 6, 15 March 2001 (2001-03-15), pages 721-726, XP002251651 ISSN: 0002-9149
OPARIL SUZANNE ET AL: "Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension." CLINICAL THERAPEUTICS, vol. 18, no. 4, 1996, pages 608-625, XP002251652 ISSN: 0149-2918
OHNISHI K ET AL: "Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: Comparison with a calcium channel blocker." INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, vol. 39, no. 10, October 2001 (2001-10), pages 417-422, XP008020851 ISSN: 0946-1965
SONG J C, WHITE M: "Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists" PHARMACOTHERAPY, vol. 20, no. 2, 2000, pages 130-139,
[Online] Retrieved from the Internet: URL:http://www.pharma.us.novartis.com/news room/pressReleases/releaseDetail.jsp?PRID= 1996>
WELLINGTON K, FAULDS D M: "Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension" DRUGS, vol. 62, no. 13, 2002, pages 1983-2005,

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).